NCCN Pharmacy Updates: Navigating Advances in Targeted Therapies for Advanced Esophageal, Esophagogastric Junction (EGJ) and Gastric Cancers
The standards of care in the first-line setting for the treatment of advanced or metastatic esophageal, esophagogastric junction and gastric cancer are evolving rapidly. There is a need to review the current landscape of treatment regimens and understand how to incorporate the new standards of care to effectively treat this patient population.
Archived Monthly Oncology Tumor Boards: Optimal Multidisciplinary Management of Advanced Esophageal Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.
Monthly Oncology Tumor Boards: Optimal Multidisciplinary Management of Advanced Esophageal Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care of patients with esophageal cancer.
NCCN Guidelines® Updates: Gastric and Esophageal Cancers
Decisions regarding treatment for advanced or metastatic gastroesophageal cancers require that clinicians be familiar with new and existing chemotherapy agents and targeted therapies as well as the current evidence regarding the survival rates and toxicities associated with various treatment approaches.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care. In addition, clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies become available.
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer
Clinicians must consider disease stage, histology, biomarker expression and patient performance status to make decisions regarding optimal care. In addition, clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies become available.
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer

Join David H. Ilson, MD, PhD and Laura H. Tang, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to gastric cancer.

Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Gastric Cancer

Join David H. Ilson, MD, PhD and Laura H. Tang, MD, PhD from Memorial Sloan Kettering Cancer Center as they present their expertise on a range of cases pertaining to gastric cancer.

Multidisciplinary Management of Esophageal and Esophagogastric Junction (EGJ) Cancers

This information was originally presented at the NCCN 2017 Oncology Fellows Program: New Horizons in Quality Cancer Care™ held on March 26, 2017.

Multimodality Therapy of Localized Gastric Adenocarcinoma

Surgical resection is the primary method of obtaining a potential cure for patients with gastric adenocarcinoma. However, chemotherapy or chemoradiotherapy offer significant improvement in survival over surgery alone.

Pages

Subscribe to RSS - Gastric/Esophageal Cancer